These findings support the promotion of antitumor activity through the blockade of the immune checkpoint ligand CD200, resulting in a dose-dependent decrease in CD200 overexpression in CLL cells owing to the binding of samalizumab to CD200. Here, CD200 is linked to B-cell chronic lymphocytic leukemia.